Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder

Objective: to assess the clinical and economic efficiency and impact on the budget when using the drug Mirabegron in the treatment of an overactive bladder.
Materials and methods. Study design — retrospective analysis of published data. Pharmacoeconomic analysis methods — cost analysis, clinical and economic analysis, budget impact analysis.
Results. Despite the fact that the drug Mirabegron for the treatment of overactive bladder is less effective in comparison with the use of the botulinum toxin type A-hemagglutinin complex drug, the clinical and economic analysis showed that within the horizon of 12 months the use of the drug Mirabegron will require 66.8 % less costs. Analysis of the impact on the budget showed that when using the drug Mirabegron from the first year in 100 % of patients, the decrease in the burden on the budget will be 66.8 %. Gradual provision of Mirabegron to patients over 3 years instead of Botulinum toxin type A-hemagglutinin complex will reduce the burden on the budget by 44.4 % in 3 years. Sensitivity analysis showed that the results obtained are resistant to changes in prices for compared drugs and a decrease in the volume of therapy with botulinum toxin type A-hemagglutinin complex.
Conclusion. The use of the drug Mirabegron in the treatment of patients with an overactive bladder is pharmacoeconomically justified. The inclusion of Mirabegron in the lists of medicines, the costs of which are subject to state reimbursement, is advisable.

1. Клинические рекомендации «Недержание мочи». Министерство здравоохранения РФ. Российское общество урологов. Москва, 2020. [Klinicheskie rekomendacii «Nederzhanie mochi». Ministry of Health of the Russian Federation. Russian Society of Urologists. Moscow, 2020. (In Russ).]

2. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int. 2004 Feb;93(3):324-30. DOI: 10.1111/j.1464-410x.2003.04609.x

3. Коршунова Е.С. Новое слово в лечении больных гиперактивным мочевым пузырем. Мирабегрон: прошлое, настоящее, будущее // Урология. 2018;(5):170-174. [Korshunova ES. New approach to the treatment of patients with overactive bladder. Mirabegron: past, present and future. Urologiia. 2018;(5):170-174. (In Russ).] DOI: 10.18565/urology.2018.5.170-174

4. Инструкция по медицинскому применению препарата Бетмига (мирабегрон) [Instructions for the medical use of the drug Betmiga (mirabegron) (In Russ).] Доступно по: https://clck.ru/TsNwu Ссылка активна на 23.03.2021.

5. Постановление Правительства РФ от 28.08.2014 N 871 (ред. от 20.11.2018) «Об утверждении Правил формирования перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». [Resolution of the Government of the Russian Federation of 28.08.2014 N 871 (ed. of 20.11.2018) «Ob utverzhdenii Pravil formirovaniya perechnej lekarstvennyh preparatov dlya medicinskogo primeneniya i minimal’nogo assortimenta lekarstvennyh preparatov, neobhodimyh dlya okazaniya medicinskoj pomoshchi». (In Russ).]

6. Постановление Правительства РФ от 29 октября 2018 г. № 1283 «О внесении изменений в правила формирования Перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». Москва [Resolution of the Government of the Russian Federation No. 1283 of October 29, 2018 «O vnesenii izmenenij v pravila formirovaniya Perechnej lekarstvennyh preparatov dlya medicinskogo primeneniya i minimal’nogo assortimenta lekarstvennyh preparatov, neobhodimyh dlya okazaniya medicinskoj pomoshchi». Moscow. (In Russ).]

7. Постановление Правительства РФ от 3 декабря 2020 г. № 2021 «О внесении изменений в правила формирования Перечней лекарственных препаратов для медицинского применения и минимального ассортимента лекарственных препаратов, необходимых для оказания медицинской помощи». Москва [Decree of the Government of the Russian Federation No. 2021 of December 3, 2020 «O vnesenii izmenenij v pravila formirovaniya Perechnej lekarstvennyh preparatov dlya medicinskogo primeneniya i minimal’nogo assortimenta lekarstvennyh preparatov, neobhodimyh dlya okazaniya medicinskoj pomoshchi». Moscow. (In Russ).]

8. Wesnes KA et al. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin Drug Saf. 2009 Nov;8(6):615-26. DOI: 10.1517/14740330903260790

9. Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, Glanville JM, Fleetwood K, James D, Chapple CR. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network metaanalysis. BJU Int. 2017 Nov;120(5):611-622. DOI: 10.1111/bju.13945

10. Инструкция по медицинскому применению препарата Лантокс [Instructions for the medical use of the drug Lantox. (In Russ).] Доступно по: https://clck.ru/TsPey Ссылка активна на 23.03.2021

11. Инструкция по медицинскому применению препарата Ботокс [Instructions for the medical use of Botox (In Russ).] Доступно по: https://clck.ru/TscH7 Ссылка активна на 23.03.2021

12. López Ramos H, Torres Castellanos L, Ponce Esparza I, Jaramillo A, Rodríguez A, Moreno Bencardino C. Management of Overactive Bladder With OnabotulinumtoxinA: Systematic Review and Meta-analysis. Urology. 2017 Feb;100:53-58. DOI: 10.1016/j.urology.2016.10.026

13. Flynn MK, Amundsen CL, Perevich M, et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009 Jun; 181(6): 2608-15. DOI: 10.1016/j.juro.2009.01.117

14. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010 Dec;184(6):2416-22. DOI: 10.1016/j.juro.2010.08.021

15. Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, Hermieu JF, Amarenco G, Karsenty G, Saussine C, Barbot F; VESITOX study group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012 Mar;61(3):520-9. DOI: 10.1016/j.eururo.2011.10.028.

16. Dowson C, Sahai A, Watkins J, Dasgupta P, Khan MS. The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. Int J Clin Pract. 2011 Jun;65(6):698-704. DOI: 10.1111/j.1742-1241.2011.02663.x

17. Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013 Aug;64(2):249-56. DOI: 10.1016/j.eururo.2013.04.001

18. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022

19. Cui Y, Wang L, Liu L, Zeng F, Niu J, Qi L, Chen H. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and metaanalysis. Urol Int. 2013;91(4):429-38. DOI: 10.1159/000351037

20. Lozano-Ortega G, Walker D, Rogula B, Deighton A, Johnston K, Hawkins N, Dmochowski R. The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis. Urology. 2019 May;127:1-8. DOI: 10.1016/j.urology.2019.02.005

21. О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2021 год и на плановый период 2022 и 2023 годов. Постановления правительства РФ от 28.12.2020 г. №2299. Москва, 2020. [On the Program of state guarantees of free provision of medical care to citizens for 2021 and for the planning period of 2022 and 2023. Decree of the Government of the Russian Federation No. 2299 of 28.12.2020. Moscow, 2020. (In Russ).]

22. Государственный реестр предельных отпускных цен. [State Register of maximum selling prices. (In Russ).] Доступно по: https://grls.rosminzdrav.ru/pricelims.aspx Ссылка активна на 23.03.2021

23. Касян Г.Р., Куприянов Ю.А., Ходырева Л.А., Дударева А.А. Cиндром гиперактивного мочевого пузыря в клинической практике врача-уролога. Методические рекомендации № 13. Москва, 2019. [Kasyan GR, Kupriyanov YuA, Khodyreva LA, Dudareva AA. Cindrom giperaktivnogo mochevogo puzyrya v klinicheskoj praktike vracha-urologa. Metodicheskie rekomendacii № 13. Moscow, 2019 (In Russ).]

24. Freemantle N, Ginsberg DA, McCool R, Fleetwood K, Arber M, Khalaf K, Loveman C, Ni Q, Glanville J. Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison. BMJ Open. 2016 Feb 23;6(2):e009122. DOI: 10.1136/bmjopen-2015-009122

25. Каприн А.Д., Аполихин О.И., Сивков А.В., Москалева Н.Г., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за 2003-2013 гг. // Экспериментальная и клиническая урология. 2015;(2):4-12. [Kaprin AD, Apolikhin OI, Sivkov AV, Moskaleva NG, Solntseva TV, Komarova VA. Analysis of uronephrological morbidity and mortality in Russian Federation for 2003- 2013. Eksperimental’naya i klinicheskaya urologiya. 2015;(2):4-12. (In Russ).]